miR-21在非酒精性脂肪肝病中的研究进展
Research Progress of miR-21 in Non-Alcoholic Fatty Liver Disease
DOI: 10.12677/ACM.2022.12121673, PDF,    科研立项经费支持
作者: 彭 冉, 郭 巧, 高 韬, 柯大智*：重庆医科大学附属第二医院全科医学科，重庆
关键词: 非酒精性脂肪性肝病；微小RNA；发病机制；早期诊断；文献综述；Nonalcoholic Fatty Liver Disease； miRNA； Pathogenesis； Early Diagnosis； Review
摘要: 非酒精性脂肪性肝病(non-alcoholic fatty liver disease, NAFLD)是最常见的慢性肝病之一，早期症状隐匿，疾病发展后期可严重危害人体健康。微小RNA (miRNA)是一种由少量核苷酸组成的非编码RNA，在多种生物过程中发挥重要作用。微小RNA-21 (miR-21)与NAFLD的发生发展有着紧密联系。目前，NAFLD的发病机制尚不清楚，临床上缺乏特异性的早期诊断方法。本文就miR-21在NAFLD发生发展中的作用机制进行综述，并探讨其在NAFLD早期诊断中的价值。
Abstract: Non-alcoholic Fatty Liver Disease (NAFLD) is one of the most common chronic liver diseases in the world. The early symptoms are occult and the later stages of disease development can seriously harm human health. At present, the specific pathogenesis of NAFLD is not clear, and there is a lack of specific clinical early diagnosis methods. MicroRNAs (miRNAs) are non-coding RNAs composed of a small number of nucleotides that play an important role in a variety of biological processes. Pre-vious studies have shown that MicroRNA-21 (miR-21) is closely related to the occurrence and de-velopment of NAFLD. This paper reviews the mechanism of miR-21 in the occurrence and develop-ment of NAFLD, and discusses its value in the early diagnosis of NAFLD.
文章引用：彭冉, 郭巧, 高韬, 柯大智. miR-21在非酒精性脂肪肝病中的研究进展[J]. 临床医学进展, 2022, 12(12): 11611-11617. https://doi.org/10.12677/ACM.2022.12121673

参考文献

[1] 中华医学会内分泌学分会. 非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版) [J]. 临床肝胆病杂志, 2018, 34(10): 2103-2108.
[2] Li, J., Zou, B., Yeo, Y.H., Feng, Y., Xie, X., Lee, D.H., et al. (2019) Prevalence, Incidence, and Outcome of Non-Alcoholic Fatty Liver Disease in Asia, 1999-2019: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology and Hepatology, 4, 389-398. [Google Scholar] [CrossRef] 
[3] Lee, R.C., Feinbaum, R.L. and Ambros, V. (1993) The C. elegans Heterochronic Gene lin-4 Encodes Small RNAs with An-tisense Complementarity to lin-14. Cell, 75, 843-854. [Google Scholar] [CrossRef] 
[4] Iaquinta, M.R., Lanzillotti, C., Mazziotta, C., Bononi, I., Frontini, F., Mazzoni, E., et al. (2021) The Role of microRNAs in the Osteogenic and Chondrogenic Differentiation of Mesenchymal Stem Cells and Bone Pathologies. Theranostics, 11, 6573-6591. [Google Scholar] [CrossRef] [PubMed]
[5] Nowosad, K., Hordyjewska-Kowalczyk, E. and Tylzanowski, P. (2020) Mutations in Gene Regulatory Elements Linked to Human Limb Malformations. Journal of Medical Genetics, 57, 361-370. [Google Scholar] [CrossRef] [PubMed]
[6] Huang, P., He, X.-Y. and Xu, M. (2020) The Role of miR-NA-146a and Proinflammatory Cytokines in Carotid Atherosclerosis. BioMed Research International, 2020, Article ID: 6657734. [Google Scholar] [CrossRef] [PubMed]
[7] Kondkar, A.A. and Abu-Amero, K.K. (2015) Utility of Cir-culating microRNAs as Clinical Biomarkers for Cardiovascular Diseases. BioMed Research International, 2015, Article ID: 821823. [Google Scholar] [CrossRef] [PubMed]
[8] Lagos-Quintana, M., Rauhut, R., Lendeckel, W. and Tuschl, T. (2001) Identification of Novel Genes Coding for Small Expressed RNAs. Science, 294, 853-858. [Google Scholar] [CrossRef] [PubMed]
[9] Surina, S., Fontanella, R.A., Scisciola, L., Marfella, R., Paolisso, G. and Barbieri, M. (2021) miR-21 in Human Cardiomyopathies. Frontiers in Cardiovascular Medicine, 8, Article ID: 767064. [Google Scholar] [CrossRef] [PubMed]
[10] Ludwig, N., Leidinger, P., Becker, K., Backes, C., Fehlmann, T., Pallasch, C., et al. (2016) Distribution of miRNA Expression across Human Tissues. Nucleic Acids Research, 44, 3865-3877. [Google Scholar] [CrossRef] [PubMed]
[11] Loyer, X., Paradis, V., Hénique, C., Vion, A.-C., Colnot, N., Guerin, C.L., et al. (2016) Liver microRNA-21 Is Overexpressed in Non-Alcoholic Steatohepatitis and Contributes to the Disease in Experimental Models by Inhibiting PPARα Expression. Gut, 65, 1882-1894. [Google Scholar] [CrossRef] [PubMed]
[12] Zhang, Z., Zha, Y., Hu, W., Huang, Z., Gao, Z., Zang, Y., et al. (2013) The Autoregulatory Feedback Loop of microRNA-21/Programmed Cell Death Protein 4/Activation Protein-1 (MiR-21/PDCD4/AP-1) as a Driving Force for Hepatic Fibrosis Development. Journal of Biological Chemistry, 288, 37082-37093. [Google Scholar] [CrossRef] 
[13] Tang, J., Li, X., Cheng, T. and Wu, J. (2021) miR-21-5p/SMAD7 Axis Promotes the Progress of Lung Cancer. Thoracic Cancer, 12, 2307-2313. [Google Scholar] [CrossRef] [PubMed]
[14] Arghiani, N. and Matin, M.M. (2021) miR-21: A Key Small Mole-cule with Great Effects in Combination Cancer Therapy. Nucleic Acid Therapeutics, 31, 271-283. [Google Scholar] [CrossRef] [PubMed]
[15] Hong, Y., Ye, M., Wang, F., Fang, J., Wang, C., Luo, J., et al. (2021) MiR-21-3p Promotes Hepatocellular Carcinoma Progression SMAD7/YAP1 Regulation. Frontiers in Oncology, 11, Ar-ticle ID: 642030. [Google Scholar] [CrossRef] [PubMed]
[16] Parlati, L., Régnier, M., Guillou, H. and Postic, C. (2021) New Targets for NAFLD. JHEP Reports, 3, Article ID: 100346. [Google Scholar] [CrossRef] [PubMed]
[17] Wu, H., Ng, R., Chen, X., Steer, C.J. and Song, G. (2016) MicroRNA-21 Is a Potential Link between Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma via Modulation of the HBP1-p53-Srebp1c Pathway. Gut, 65, 1850-1860. [Google Scholar] [CrossRef] [PubMed]
[18] Calo, N., Ramadori, P., Sobolewski, C., Romero, Y., Maeder, C., Fournier, M., et al. (2016) Stress-Activated in Hepatocytes Promotes Lipid and Glucose Metabolic Disorders Associated with High-Fat Diet Consumption. Gut, 65, 1871-1881. [Google Scholar] [CrossRef] [PubMed]
[19] 赵晓云, 邵凯. 微小RNA-21在胰岛素抵抗和糖尿病伴发非酒精性脂肪肝发病中的作用[J]. 中国医学科学院学报, 2016, 38(2): 144-149.
[20] Zhang, X., Deng, F., Zhang, Y., Zhang, X., Chen, J. and Jiang, Y. (2021) PPARγ Attenuates He-patic Inflammation and Oxidative Stress of Non-Alcoholic Steatohepatitis via Modulating the miR-21-5p/SFRP5 Path-way. Molecular Medicine Reports, 24, Article No. 823. [Google Scholar] [CrossRef] [PubMed]
[21] Oh, C.J., Kim, J.-Y., Min, A.-K., Park, K.-G., Harris, R.A., Kim, H.-J., et al. (2012) Sulforaphane Attenuates Hepatic Fibrosis via NF-E2-Related Factor 2-Mediated Inhibition of Transforming Growth Factor-β/Smad Signaling. Free Radical Biology and Medicine, 52, 671-682. [Google Scholar] [CrossRef] [PubMed]
[22] Mishra, P.J. and Bertino, J.R. (2009) MicroRNA Polymorphisms: The Future of Pharmacogenomics, Molecular Epidemiology and Individualized Medicine. Pharmacogenomics, 10, 399-416. [Google Scholar] [CrossRef] [PubMed]
[23] Fabregat, I. and Ca-ballero-Díaz, D. (2018) Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogene-sis. Frontiers in Oncology, 8, Article 357. [Google Scholar] [CrossRef] [PubMed]
[24] Zhou, X.-L., Xu, H., Liu, Z.-B., Wu, Q.-C., Zhu, R.-R. and Liu, J.-C. (2018) miR-21 Promotes Cardiac Fibroblast-to-Myofibroblast Transfor-mation and Myocardial Fibrosis by Targeting Jagged1. Journal of Cellular and Molecular Medicine, 22, 3816-3824. [Google Scholar] [CrossRef] [PubMed]
[25] Friedman, S.L. (2008) Mechanisms of Hepatic Fibrogenesis. Gastroenterology, 134, 1655-1669. [Google Scholar] [CrossRef] [PubMed]
[26] Derynck, R. and Zhang, Y.E. (2003) Smad-Dependent and Smad-Independent Pathways in TGF-β Family Signalling. Nature, 425, 577-584. [Google Scholar] [CrossRef] [PubMed]
[27] He, X., Xie, J., Zhang, D., Su, Q., Sai, X., Bai, R., et al. (2015) Recom-binant Adeno-Associated Virus-Mediated Inhibition of microRNA-21 Protects Mice Against the Lethal Schistosome In-fection by Repressing Both IL-13 and Transforming Growth Factor Beta 1 Pathways. Hepatology (Baltimore, MD), 61, 2008-2017. [Google Scholar] [CrossRef] [PubMed]
[28] Nakao, A., Afrakhte, M., Morén, A., Nakayama, T., Christian, J.L., Heuchel, R., et al. (1997) Identification of Smad7, a TGFβ-Inducible Antagonist of TGF-Beta Signalling. Nature, 389, 631-635. [Google Scholar] [CrossRef] [PubMed]
[29] Jarman, E.J. and Boulter, L. (2020) Targeting the Wnt Signaling Pathway: The Challenge of Reducing Scarring without Affecting Repair. Expert Opinion on Investigational Drugs, 29, 179-190. [Google Scholar] [CrossRef] [PubMed]
[30] Tang, M., Jia, H., Chen, S., Yang, B., Patpur, B.K., Song, W., et al. (2021) Significance of MR/OPN/HMGB1 Axis in NAFLD-Associated Hepatic Fibrogenesis. Life Sciences, 264, Article ID: 118619. [Google Scholar] [CrossRef] [PubMed]
[31] Wu, K., Ye, C., Lin, L., Chu, Y., Ji, M., Dai, W., et al. (2016) In-hibiting miR-21 Attenuates Experimental Hepatic Fibrosis by Suppressing Both the ERK1 Pathway in HSC and Hepato-cyte EMT. Clinical Science (Lond), 130, 1469-1480. [Google Scholar] [CrossRef] 
[32] Volinia, S., Calin, G.A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., et al. (2006) A microRNA Expression Signature of Human Solid Tumors Defines Cancer Gene Targets. Proceedings of the National Academy of Sciences of the United States of America, 103, 2257-2261. [Google Scholar] [CrossRef] [PubMed]
[33] Zhou, Y., Ren, H., Dai, B., Li, J., Shang, L., Huang, J., et al. (2018) Hepatocellular Carcinoma-Derived Exosomal miRNA-21 Contributes to Tumor Progression by Converting Hepatocyte Stellate Cells to Cancer-Associated Fibroblasts. Journal of Experimental & Clinical Cancer Research, 37, Article No. 324. [Google Scholar] [CrossRef] [PubMed]
[34] Zhu, Q., Wang, Z., Hu, Y., Li, J., Li, X., Zhou, L., et al. (2012) miR-21 Promotes Migration and Invasion by the miR-21-PDCD4-AP-1 Feedback Loop in Human Hepatocellular Car-cinoma. Oncology Reports, 27, 1660-1668. [Google Scholar] [CrossRef] [PubMed]
[35] Wang, J., Chu, Y., Xu, M., Zhang, X., Zhou, Y. and Xu, M. (2019) miR-21 Promotes Cell Migration and Invasion of Hepatocellular Carcinoma by Targeting KLF5. Oncology Letters, 17, 2221-2227. [Google Scholar] [CrossRef] [PubMed]
[36] Yoon, J.S., Kim, G., Lee, Y.R., Park, S.Y., Tak, W.Y., Kweon, Y.-O., et al. (2018) Clinical Significance of microRNA-21 Expression in Disease Progression of Patients with Hepatocellular Carcinoma. Biomarkers in Medicine, 12, 1105-1114. [Google Scholar] [CrossRef] [PubMed]
[37] Wagenaar, T.R., Zabludoff, S., Ahn, S.-M., Allerson, C., Arlt, H., Baffa, R., et al. (2015) Anti-miR-21 Suppresses Hepatocellular Carcinoma Growth via Broad Transcriptional Network Deregulation. Molecular Cancer Research, 13, 1009-1021. [Google Scholar] [CrossRef] 
[38] Arrese, M., Eguchi, A. and Feldstein, A.E. (2015) Circu-lating microRNAs: Emerging Biomarkers of Liver Disease. Seminars in Liver Disease, 35, 43-54. [Google Scholar] [CrossRef] [PubMed]
[39] Yamada, H., Suzuki, K., Ichino, N., Ando, Y., Sawada, A., Osakabe, K., et al. (2013) Associations between Circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and Non-Alcoholic Fatty Liver. Clinica Chimica Acta, 424, 99-103. [Google Scholar] [CrossRef] [PubMed]
[40] Becker, P.P., Rau, M., Schmitt, J., Malsch, C., Hammer, C., Bantel, H., et al. (2015) Performance of Serum microRNAs-122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis. PLOS ONE, 10, e0142661. [Google Scholar] [CrossRef] [PubMed]
[41] Sun, C., Huang, F., Liu, X., Xiao, X., Yang, M., Hu, G., et al. (2015) miR-21 Regulates Triglyceride and Cholesterol Metabolism in Non-Alcoholic Fatty Liver Disease by Targeting HMGCR. International Journal of Molecular Medicine, 35, 847-853. [Google Scholar] [CrossRef] [PubMed]
[42] Zhang, H., Ding, R. and Chen, D. (2021) Value of miR-21 Levels as Potential Biomarkers in the Early Diagnosis of Hepatocellular Carcinoma: A Meta-Analysis. Biomarkers, 26, 586-597. [Google Scholar] [CrossRef] 
[43] Jenike, A.E. and Halushka, M.K. (2021) miR-21: A Non-Specific Biomarker of All Maladies. Biomarker Research, 9, Article No. 18. [Google Scholar] [CrossRef] [PubMed]

为你推荐